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Focal and segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome in children and adults throughout the world. In the
past 50 years, significant advances have been made in the identification and characterization of familial forms of nephrotic syndrome and FSGS.
Resultant to these pursuits, several podocyte structural proteins such as nephrin, podocin, alpha-actinin 4 (ACTN4), and CD2-associated protein
(CD2AP) have emerged to provide critical insight into the pathogenesis of hereditary nephrotic syndromes. The latest advance in familial FSGS
has been the discovery of a mutant form of canonical transient receptor potential cation channel 6 (TRPC6), which causes an increase in calcium
transients and essentially a gain of function in this cation channel located on the podocyte cell membrane. The TRP ion channel family is a diverse
group of cation channels united by a common primary structure which contains six membrane-spanning domains, with both carboxy and amino
termini located intracellularly. TRP channels are unique in their ability to activate independently of membrane depolarization. TRPC6 channels
have been shown to be activated via phospholipase C stimulation. The mechanisms by which mutant TRPC6 causes an increase in intracellular
calcium and leads to glomerulosclerosis are unknown. Mutant TRPC6 may affect critical interactions with the aforementioned podocyte structural
proteins, leading to abnormalities in the slit diaphragm or podocyte foot processes. Mutant TRPC6 may also amplify injurious signals mediated by
Ang II, a common final pathway of podocyte apoptosis in various mammalian species. Current evidence also suggests that blocking TRPC6
channels may be of therapeutic benefit in idiopathic FSGS, a disease with a generally poor prognosis. Preliminary experiments reveal the
commonly used immunosuppressive agent FK-506 can inhibit TRPC6 activity in vivo. This creates the exciting possibility that blocking TRPC6
channels within the podocyte may translate into long-lasting clinical benefits in patients with FSGS.
© 2007 Elsevier B.V. All rights reserved.Keywords: Familial focal segmental glomerulosclerosis; Familial nephropathy; Genetic; Kidney; Hereditary; TRPC6; Podocin; Nephrin; ACTN4; CD2AP1. Introduction
Nephrotic syndrome is a clinical entity defined by the triad of
edema, proteinuria, and hypercholesterolemia. Focal segmental
glomerulosclerosis is a common cause of nephrotic syndrome,
both in children, where it accounts for 7 to 20% of cases, and in
adults, where it accounts for up to 35% of cases [1]. Studies
performed at several large institutions have documented an
increased incidence of FSGS in biopsies of adult patients and it
is the leading cause of idiopathic nephrotic syndrome among
black individuals [2]. Furthermore, despite aggressive therapy,
idiopathic FSGS often leads to end-stage renal disease (ESRD).⁎ Corresponding author. Duke University Medical Center, Duke Box 2903,
Durham, NC 27710, USA. Tel.: +1 919 660 2183; fax: +1 919 684 0920.
E-mail address: michelle.winn@duke.edu (M.P. Winn).
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.03.005Classically, the clinicopathologic syndrome has been defined as
either primary (idiopathic), secondary or familial. Well-known
medical maladies associated with secondary FSGS have been
established, including human immunodeficiency virus infec-
tion, heroin abuse, sickle cell disease, and obesity [1,3–6].
Familial forms of FSGS include autosomal dominant and
recessive patterns of inheritance and those associated with
congenital syndromes such as Laurence–Moon–Biedl and
Charcot–Marie–Tooth [7,8]. Over the past 50 years, significant
advances have been made in the identification and character-
ization of familial forms of FSGS. Through the use of advanced
molecular genetic cloning techniques, several mutations have
been found in key podocyte proteins including nephrin,
podocin, ACTN4, and CD2AP (Table 1). These proteins have
typically been involved in podocyte signaling or the structural
apparatus of the slit diaphragm, the key filtration barrier of the
Table 1
Currently known genes that cause inherited nephrotic syndrome and FSGS
Name (OMIM*) Associated disorder Chromosomal
location
Pattern of
inheritance
Clinical features Structure/function Ref.
Nephrin (NPHS1) Congenital
nephrotic syndrome
of the Finnish type
19q13 AR Massive proteinuria in
utero with high mortality
rate
Transmembrane adhesion protein
localizes to lipid rafts within
the slit diaphragm of the podocyte
[14–16]
Podocin (NPHS2) Steroid-resistant
nephrotic syndrome
1q25–q31 AR Proteinuria between 3 months
and 5 years of age with
rapid progression to ESRD
Structural protein that recruits
nephrin and CD2AP to lipid rafts
in the slit diaphragm
[21]
Alpha-actinin
4 (FSGS1)
Hereditary FSGS 19q13 AD Adult onset FSGS with
variable age of onset, severity,
and progression to ESRD
Actin-binding protein that binds
actin to the cell membrane of
the podocyte
[29]
Transient Receptor
Potential Cation
Channel
6 (FSGS2)
Hereditary FSGS 11q21–22 AD High grade proteinuria in 3rd to
4th decade with ESRD in 60%
within 10 years of diagnosis
Relatively non-selective cation
channel that associates with
nephrin, podocin, and CD2AP at
the slit diaphragm
[9]
CD2-associated
protein (FSGS3)
FSGS 6p12 Haplo-insufficiency FSGS Scaffold protein that interacts with
the cytoplasmic domain of nephrin
[29]
AR: autosomal recessive. AD: autosomal dominant.
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FSGS has been the discovery of a mutant variant of TRPC6 in a
large New Zealand kindred [9]. This mutation causes an
autosomal dominant form of hereditary FSGS which is
particularly aggressive. It is characterized by high grade
proteinuria by the third or fourth decade of life and ESRD in
60% of affected individuals. The TRPC6 mutation involves a
proline to glutamine substitution at amino acid 112 in the
protein, causing an increase in calcium transients. It appears that
there is a mislocation of the ion channels to the podocyte cell
membrane. This is the first ion channel identified as a cause of
FSGS. Furthermore, these findings add to the growing spectrum
of disease caused by abnormal calcium homeostasis, and more
specifically, by mutations in TRP channels. FSGS joins
hypomagnesemia with secondary hypocalcemia (TRPM6)
[10], mucolipidosis type IV (TRPML1) [11], and polycystic
kidney disease (TRPP1 and TRPP2) [12] in a fairly new
category of diseases, the TRP channelopathies.
2. Hereditary nephrotic syndromes
2.1. Nephrin mutation
Familial forms of FSGS have been known since the 1950s,
but it has only been over the last 10 years that specific genetic
defects have been discovered, largely due to advances in
molecular biology and human genetics. The earliest gene
known to be associated with a hereditary nephrotic syndrome is
nephrin (NPHS1), whose mutations cause congenital nephrotic
syndrome of the Finnish type, an autosomal recessive disease
affecting approximately 1:10,000 newborns in Finland [13–15].
Of the fifty mutations discovered, the two most common are a
frameshift mutation and a nonsense mutation, Fin major and Fin
minor, both of which cause a premature stop codon [16]. The
nephrin protein is a 180 kDa transmembrane protein exclusively
expressed by glomerular podocytes within the kidney and is
predominantly localized to the glomerular slit diaphragm [17–
19]. Nephrin is also expressed in brain and pancreatic tissue.Immunoelectron microscopy has revealed that nephrin is
present in junctions with ladder-like structures between the
differentiated podocytes [20]. These structures are absent if the
mutated form of the gene is present.
2.2. Podocin mutation
Podocin (NPHS2) mutations were next discovered as a cause
of a hereditary nephrotic syndrome. Patients with mutations in
podocin have an autosomal recessive, mostly steroid-resistant
nephrotic syndrome [21]. These patients show disease onset in
early childhood and rapid progression to ESRD. Podocin, a 42-
kDa protein in the lipid raft-associated stomatin protein family,
is predicted to form a membrane-associated hairpin-like
structure with a cytosolic amino and carboxy terminal domain.
Podocin has been shown to localize on podocyte foot process
membranes at the insertion site of the slit diaphragm [22]. It
accumulates in an oligomeric form in lipid rafts of the slit
diaphragm. In vivo studies demonstrate that it interacts via its
carboxy terminal domain with other podocyte proteins such as
nephrin and CD2AP [23]. The interaction between nephrin and
podocin is required for the proper initiation of nephrin
signaling. Targeted disruptions of podocin inhibit both nephrin
trafficking and nephrin-initiated signal transduction, thereby
altering normal podocyte homeostasis [24].
2.3. CD2AP and ACTN4
Other relevant podocyte proteins associated with familial
FSGS include CD2AP and ACTN4. CD2AP, a mouse
homologue of the human p130(Cas) ligand, contains multiple
SH3-binding domains that enhance CD2 clustering via its
cytoplasmic tail. It is located in the membranes of T cells and
natural killer cells where it facilitates T-cell adhesion to antigen-
presenting cells [25]. CD2AP knock-out mice studies have
shown compromised immune function and nephrotic syndrome
with renal failure at 6 to 7 weeks of age. Post-mortem studies
revealed that CD2AP is expressed primarily in glomerular
Fig. 1. The unique shape of the podocyte is due to the actin cytoskeleton that contains a dense network of F-actin and myosin (M), besides several actin-binding
proteins such as synaptopodin (S), and α-actinin-4 (ACTN4). The podocyte consists of three membrane domains namely, apical, basal, and junctional, based on the
molecular anatomy of the site [97]. The junctional membrane domain proteins include nephrin whose cytoplasmic tail binds to podocin, while CD2AP co-localizes in
the same domain with nephrin. Other proteins such as Neph-1, Neph-2, Neph-3, FAT1, ZO-1, densin and β-cadherin are also localized to this domain. TRPC6
associates with podocin and nephrin at the slit diaphragm. One of the key surface receptors, angiotensin receptor 1 (AT1) is shown. The apical membrane domain is
negatively charged due to the presence of surface anionic proteins such as podocalyxin, podoplanin, podoendin, and GLEPP (glomerular epithelial protein 1) which
effectively prevents the passage of albumin. The basal membrane domain consists of α3β1 integrin and α- and β-dystroglycans to anchor the podocyte in the GBM
(glomerular basement membrane) and also to help connect certain matrix proteins (such as agrin and laminin 11) within the GBM. The GBM is composed mainly of
collagen IV (α3, α4, α5) and other matrix proteins mentioned above. The α3β1 integrin dimers connect the TPV (talin, paxillin, and vinculin) complex to laminin 11.
The α- and β-dystroglycans connect utrophin to agrin. Other key molecules shown in various compartments include Cas (p130Cas), ezrin (EZ), focal adhesion kinase
(FAK), integrin-linked kinase (ILK), Na+–H+ exchange regulatory factor (N) and the non-selective cation channel (NSCC). G-protein coupled receptor (GPCR)-
mediated signaling pathways play a major role in various functional activities of the podocytes (modified and updated from Pavenstadt et al., [70] and Kriz [98] as well
as other literature mentioned in the text and legend) [70,98].
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exhibit defects in foot processes, accompanied by mesangial
cell hyperplasia and extracellular matrix deposition [26]. More
recent mouse studies have revealed CD2AP's interaction with
other podocyte proteins including fyn and synaptopodin. Huber
et al. showed that combinations of CD2AP heterozygosity, andeither fyn or synaptopodin heterozygosity, resulted in sponta-
neous proteinuria and in FSGS-like glomerular damage [27].
This genetic epistasis was followed by immunoprecipitation
experiments which demonstrated a physical interaction between
CD2AP and the two other podocyte proteins. The specificity of
this interaction was shown by combining heterozygosity at
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localized to the slit diaphragm, with CD2AP heterozygosity and
showing no glomerular abnormalities or proteinuria. In humans,
Kirsch et al. demonstrated that p130(Cas) ligand, which shares
86% homology with mouse CD2AP, is involved in vesicle
formation and colocalizes with p130(Cas) as well as F-actin in
cell membranes [28]. Putative actin-binding sites and a coiled-
coil domain have been identified at the C terminus of the
protein, as has a putative leucine zipper motif. Kim et al.
subsequently found that splice site variations within exon 7 of
the p130(Cas) ligand gene interrupted protein translation and
led to FSGS in 2 black individuals [29]. Thus, although the
pathophysiology remains uncertain, it can be postulated that
human p130(Cas) ligand mutations lead to altered actin-binding
and abnormal podocyte cytoskeletal architecture, with resulting
proteinuria and glomerulosclerosis.
ACTN4 is located on chromosome 19q13 and encodes for a
100 kDa protein [30,31]. The function of this protein is to
crosslink and bundle actin filaments. Mutations in this gene
have been associated with autosomal dominant FSGS, char-
acterized by the adult onset of disease with variable severity and
rate of progression to ESRD. Initial studies revealed that mutant
ACTN4 binds actin filaments more strongly than wild-type
ACTN4 in vivo. Recently, it was shown that mutant protein
appears to form large aggregates within the podocyte [32]. One
model of familial FSGS in these patients would be the
development of podocyte damage as a direct effect of protein
aggregation and the toxic effects associated with this phenom-
enon, such as is observed in severe degenerative neurologic
conditions such as Alzheimer's, Parkinson's and Huntington's
diseases [33,34]. Mutant ACTN4 was also found to have a
decreased half-life in comparison to wild-type ACTN4 [32].
This would suggest another potential mechanism for familial
FSGS in patients with ACTN4 mutations that would involve the
loss of normal actin polymerization and abnormal cytoskeletal
architecture.
2.4. TRPC6 mutation
Recently, another genetic mutation was reported to be
associated with hereditary FSGS. Through whole genome
linkage analysis, fine-mapping and candidate gene screening, a
mutated gene was localized to chromosome 11q21–22 and
subsequently identified as the transient receptor potential cation
channel, subfamily C, member 6 (TRPC6) gene [9]. The
original missense mutation changed a highly conserved proline
in the first ankyrin repeat of TRPC6 to a glutamine at amino
acid 112 (P112Q). Subsequently, Reiser et al. have identified
TRPC6 mutations in five other unrelated families of diverse
ethnic origin. In each family, inheritance was consistent with an
autosomal dominant pattern and the observed amino acid
substitutions occurred in highly conserved residues throughout
evolution. Two mutations predicted amino acid substitutions in
the N-terminal intracellular domain of TRPC6; two predicted
amino acid substitutions in the C-terminal intracellular domain;
and one encoded a premature stop codon near the C terminus. In
all families, TRPC6 variant and disease inheritance followed apattern of cosegregation, with incomplete penetrance [35].
Fluorescent in situ hybridization studies in human and confocal
microscopy of rat kidney sections show broad expression of
TRPC6 throughout the kidney in tubules and glomeruli [9,35].
Recent studies have also shown that TRPC6 is expressed in
podocyte foot processes. Labeling with gold particles revealed
TRPC6 within the cell body of podocytes and in primary
processes in close vicinity to the slit diaphragm. Colocalization
studies showed that TRPC6 was associated with the aforemen-
tioned disease-causing slit diaphragm proteins nephrin, podo-
cin, and CD2AP. However, immunoblotting showed direct
biochemical interaction with only nephrin and podocin, but not
CD2AP. It appears that when nephrin was specifically deleted,
TRPC6 protein expression increased [35].
3. The TRP ion channel family
3.1. TRP ion channels
The TRP ion channels are a large class of proteins in diverse
mammalian species united by a common primary structure
which contains six membrane-spanning domain polypeptide
subunits, with both carboxy and amino termini located
intracellularly [36]. Another feature in some TRP channels is
ankyrin binding repeats at the N-terminus; ankyrin repeats fold
into structures that determine molecular identification via
protein:protein interactions. Recently, the crystal structure of
the human TRPV channel subfamily, involved in integration of
noxious stimuli, was delineated [37]. The 1.7 Å resolution
crystal structure contained a six ankyrin repeat stack with
multiple insertions in each repeat generating several unique
features, including extended loops with an exposed hydro-
phobic patch and a prominent kink. The TRPV1 ankyrin repeat
was shown to mediate interaction with two vesicular proteins,
Syt IX and Snapin, which participate in SNARE-dependent
exocytosis in excitable cells [38]. Interestingly, the TRPC6P112Q
mutation in the New Zealand cohort described by Winn et al. is
located in the first ankyrin repeat [9]. The TRP channels
mediate diverse biological functions such as mechanosensation,
ion homeostasis, cell growth, and vasoregulation [36,39–41].
They are permeable to monovalent cations as well as calcium
ions with a relative lack of selectivity. In addition, TRP channels
can be activated independent of intracellular calcium concen-
tration or membrane depolarization.
3.2. The TRPC6 (Canonical) family
The TRPC (canonical) family is expressed in a wide variety
of human tissues and can be divided into four subfamilies
(TRPC1, TRPC4, 5, TRPC3, 6, 7 and TRPC2) on the basis of
sequence homology and functional similarities. TRPC1 was the
first member of the mammalian TRP family purported to form
an ion channel [42]. Studies are conflicting with regards to
TRPC1 activation based on intracellular calcium depletion, but
it can be activated by DAG [43]. It has been shown to co-
assemble with other TRPC subunits in vitro and in vivo, where
it may be a component of different heteromeric TRP complexes
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with the autosomal recessive polycystic kidney disease protein
PKD2 [45]. The second TRPC subfamily comprises TRPC4
and TRPC5, which both contain a carboxy terminal PDZ-
binding motif not present in other TRPs [46]. PDZ domains are
peptide-binding domains that organize membrane proteins,
particularly at cell–cell junctions, including neuronal synapses.
For example, in drosophila eyes, TRP channels are organized
in a supramolecular complex along with other phototransduc-
tion proteins, such as phospholipase C (PLC) and protein
kinase C, through association with a multi-PDZ domain-
containing protein, INAD (inactivation no afterpotential D)
[47–49]. INAD contains five PDZ domains, each of which
interacts with a particular target protein and thus serves as a
scaffold to bring PLC, TRP, protein kinase C, and G-protein
together in a signaling complex. Similar multi-PDZ domain-
containing proteins exist in mammals and serve as important
protein–protein interaction sites for clustering and organization
of signaling molecules, particularly those involved in ion
transport [50–52]. For example, murine TRPM4 and TRPM5
have been shown to bind the first PDZ domain of the Na+/H+
exchanger regulatory factor (NHERF). NHERF is a two PDZ
domain-containing protein that associates with the actin
cytoskeleton via interactions with PLC isozymes and members
of the ezrin/radixin/moesin family [46]. Thus, the scaffolding
required for proper signaling of light perception in the
drosophila phototransduction system may also be required for
proper cytoskeletal architecture at the slit diaphragm of the
podocyte in mammals.
Indeed, TRPC4 and TRPC5 are heavily expressed in the
cerebral cortex of the mammalian brain [53]. Less information
is available regarding TRPC2, it appears to be a pseudogene in
humans [54]. TRPC2-deficient mice however, exhibit abnormal
mating behavior and data have shown that this channel may
have a role in pheromone signaling [55]. The TRPC3, TRPC6,
and TRPC7 subfamily are approximately 75% identical and
form a cationic non-selective channel that show both inwardly
and outwardly rectifying cation currents. TRPC6 is the most
selective of the TRP channels; the TRPC3,6,7 subfamily has
selectivity on the order of PCa/PNa 1.5 to 6:1 [36]. TRPC6
channels have been shown to be activated in response to
phospholipase C stimulation. The GPCR pathway involves
ligand binding to membrane receptors, activation of phospho-
lipase C and the generation of inositol 1,4,5 triphosphate with
binding to its receptor, and release of intracellular calcium from
the endoplasmic reticulum. Recent studies using positional
cloning have identified mutations in the PLC epsilon gene
(PLCε1) as causing early-onset nephrotic syndrome with end-
stage renal disease. Kidney histology of affected individuals
showed diffuse mesangial sclerosis and immunofluorescence
revealed an arrest in normal glomerular development [56].
Importantly, two children with truncating mutations in PLCε1
responded to therapy with corticosteroids or cyclosporine A,
indicating that molecular causes of nephrotic syndrome may be
amenable to treatment. Currently, the physiologic role of
TRPC6 channels is currently being studied through the use of
TRPC6-deficient and transgenic mouse models. Thus far,TRPC6-deficient mice have rather surprisingly been shown to
have elevated blood pressures and enhanced contractility of
isolated aortic rings and cerebral arteries [57].
4. The TRPC6 mutation causes FSGS: potential
mechanisms of disease
4.1. Alteration in podocyte dynamics
The etiology of FSGS has focused on alterations in the
structure or function of the podocyte, the visceral glomerular
epithelial cell. The podocyte is a terminally differentiated cell
that lines the outer aspect of the glomerular basement
membrane, forming the final barrier to protein loss. Individual
podocytes have foot processes which form tiny membrane
bridging filtration slits 30 to 40 nm wide, termed the slit
diaphragm. Abnormalities in podocytes may cause proteinuria
when slit diaphragm function is altered. The normal function of
the podocyte requires critical interactions between different
proteins such as nephrin, podocin, and CD2AP. For example,
extracellular immunoglobulin (Ig) domains of nephrin engage
in homophilic interactions, and form heterodimers with the Ig
domains of podocin [58–62]. As described earlier, mutations in
some of these podocyte proteins lead to nephrotic syndrome.
The TRPC6P112Q mutation augments intracellular calcium
influx into the podocyte, leading to FSGS through unclear
mechanisms. One possibility is that increased intracellular
calcium may modify the contractile structure of podocyte foot
processes, resulting in an alteration of the ultrafiltration
coefficient (Kf). It has been shown that TRPC6 is expressed
at the podocyte cell membrane and partially colocalizes with
other podocyte proteins such as nephrin and podocin.
Furthermore, these studies showed that disruption of the slit
diaphragm architecture in nephrin-deficient mice leads to
overexpression and mislocalization of TRPC6 in podocytes
[35]. This suggests that TRPC6 may be a component of an
organized signaling complex located at the slit diaphragm that
mediates normal podocyte function. Very recently, studies by
Reiser et al. have also shown a relationship between the actin
cytoskeleton and TRPC6 [63]. Cultured, differentiated podo-
cytes with TRPC6 overexpression displayed loss of actin stress
fibers. This suggests that abnormal TRPC6 expression may
cause structural changes in the slit diaphragm that could lead to
proteinuria and glomerulosclerosis. Another cause of abnormal
foot process formation may be the loss of spatial cues within the
podocyte. Li et al. have shown that brain-derived neurotrophic
factor-induced (BDNF) chemo-attraction of axonal growth
cones requires calcium signaling. Their studies in cultured
cerebellar granule cells revealed that TRPC channels contribute
to the BDNF-induced elevation of calcium at the growth cone
and are required for BDNF-induced chemo-attractive signaling.
In TRPC3 and TRPC6 deficient cells, calcium elevation and
growth cone turning were abolished [64]. Analogously, foot
process formation may require TRPC channels to act as
molecular guideposts. The TRPC6 mutation may lead to
abnormal podocyte polarity and an inability to adjust to changes
in glomerular filtration pressure. A third mechanism of
864 N. Mukerji et al. / Biochimica et Biophysica Acta 1772 (2007) 859–868abnormal podocyte contractile function may be through altered
mechanosensation. Spassova et al. have shown that TRPC6 is a
sensor of mechanically and osmotically induced membrane
stretch, independent of PLC activation [65]. The stretch
responses were blocked by the tarantula peptide, GsMTx-4,
known to specifically inhibit mechanosensitive channels by
modifying the external lipid-channel boundary. This study
suggests TRPC6 mutations may cause altered hydrostatic
pressure-driven ultrafiltration, with resultant proteinuria and
glomerulosclerosis. Huber and colleagues have shown that
TRPC6 interacts with podocin and both the MEC-2-dependent
activation of mechanosensation and that podocin-dependent
activation of TRPC channels require cholesterol. They have
speculated that multiprotein complexes containing the trans-
membrane proteins such as Neph1, Neph2, nephrin, the
cytoplasmic adaptor protein CD2AP and TRPC6 could form a
sensor involved in monitoring glomerular pressure or filtration
rate [66].
4.2. Podocytopenia
Another mechanism for the association between TRPC6 and
familial FSGS is that an alteration in the intracellular calcium
concentration may cause podocytopenia through a variety of
mechanisms, with resulting glomerulosclerosis. There is a
growing body of experimental and clinical literature that show
podocyte number is a critical determinant for the development
of glomerulosclerosis and that a decrease in podocyte number
leads to progressive renal failure [67]. Wiggins et al. have
shown that a single injection of puromycin aminonucleoside
(PAN), a podocyte toxin, caused a marked decrease in podocyte
number in rats and subsequent glomerulosclerosis [68]. Human
studies by Meyer et al. have shown that a decrease in podocyte
number in Type II diabetic Pima Indians correlated closely with
microalbuminuria, the earliest manifestation of diabetic nephro-
pathy. Follow up studies showed that decreases in podocyte
number correlated with progression of diabetic nephropathy as
well [69]. An increase in intracellular calcium may cause loss of
podocytes either through apoptosis, detachment, or lack of
proliferation [70]. Apoptosis may be caused by an ability of
mutant TRPC6 to augment the deleterious effects of Ang II.
Singhal et al. have previously shown that Ang II induces
apoptosis in cultured rat podocytes and perhaps TRPC6
upregulates this pathway of programmed cell death [71].
Detachment is another mechanism of podocyte loss. Hara and
colleagues have shown that cells obtained in the urine of
patients with various glomerular diseases stained positive for
the podocyte marker, podocalyxin [72–74]. Similar results have
been shown in a puromycin aminonucleoside nephrosis (PAN)
model of podocyte injury in rats [68]. The mechanisms of
podocyte detachment remain unknown, but likely involve the
abnormal function of specific integrins such as α3β1 integrin
[75,76]. One speculation would be that possibly an increase in
intracellular calcium affects integrin function and leads to
podocyte detachment. A third mechanism of podocyte loss is
lack of proliferation. Although podocytes are terminally
differentiated cells, proliferation is a prerequisite for normalglomerulus formation. Proliferation is governed at the level of
the cell cycle via cell cycle regulatory proteins [77]. To
proliferate, cyclins must bind to and activate partner cyclin-
dependent kinases (CDKs). In contrast, CDKs are inactivated
by CDK-inhibitors, including p21, p27, and p57 [78]. Thus, it
can be speculated that enhanced calcium entry may constitute a
pathologic trigger, such as calcium overload of the podocyte
that initiates cell death by apoptosis or causes dysregulation of
cell cycle machinery that may lead to hypertrophy of the
podocytes by altered levels of cyclins (E, A, B1) with
concurrent changes in CDKs (p27, p57) thus causing an
imbalance in the ratio of cell cycle progression and inhibiting
molecules [79].
5. Therapeutic manipulation of TRP channels
5.1. Blocking TRP channels
As stated earlier, TRP channels are a relatively new class of
ion channels which can be activated by receptor binding and/or
intracellular calcium depletion as opposed to strictly membrane
depolarization. These so-called Receptor Operated Calcium
channels (ROCs) represent a new molecular target for
therapeutic manipulation. Previous work by Beech et al. has
shown that blocking the TRPC1 channel inhibited the salient
features of vascular disease which are smooth muscle cell
proliferation and neointima formation [80]. Targeting TRPC1
may therefore represent a new therapeutic approach that avoids
the decreased peripheral vascular resistance and cardiac output
seen with the classical calcium channel blockers used as
pharmacotherapy [81]. TRPC, TRPV, and TRPM channels have
also been studied as potential drugs targets in respiratory
diseases such as chronic obstructive pulmonary disease and
asthma. It has been suggested that ROCs are involved in airway
smooth muscle contraction and specific TRP channels have
been associated with mucus hypersecretion, airway inflamma-
tion, immunomodulation, and cough production [82].
5.2. Blocking TRPC6 channels and proteinuric renal disease
With regard to FSGS and other proteinuric renal diseases,
TRPC6 may represent a new molecular target for blockade.
Classically, a fundamental line of therapy in these diseases has
been blocking of the renin–angiotensin system (RAS) system
by angiotensin-converting enzyme inhibitors (ACE) or angio-
tensin-receptor blockers (ARBs). These medications may
decrease proteinuria by altering podocyte morphology [83]. In
experimental diabetic nephropathy, podocyte foot process
broadening was ameliorated by RAS blockade [84] and was
associated with normalization of nephrin expression [85]. Given
the close association of TRPC6 and nephrin [35], blocking
TRPC6 channels may be beneficial. Furthermore, given the
augmentation in Ang II-mediated calcium influx in mutant
TRPC6 mice compared to wild-type [9], therapeutic blockade is
biologically sound. This may represent a mechanism for
targeted down-regulation of the harmful effects mediated by
Ang II. Further evidence for the potential therapeutic blockade
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shown increased expression of wild-type TRPC6 in several
non-genetic forms of human proteinuric kidney diseases,
including FSGS, minimal change disease, and membranous
nephropathy [63].
Currently, the most standard therapy for certain forms of
proteinuric renal disease, such as idiopathic FSGS are
glucocorticoids. It is also well established that idiopathic
FSGS responds poorly to such treatment [86]. Steroids have
pleiotropic effects mediated by cytoplasmic receptors that
translocate to the nucleus and activate the transcription of genes
for cytokines, chemokines, eicosanoids, and other immunomo-
dulatory substances [87–89]. Recent studies by Xing et al. have
revealed that the glucocorticoid dexamethasone has direct
effects on human podocytes. The authors used a conditionally
immortalized human podocyte cell line transfected with a
temperature-sensitive simian virus 40 transgene that when
inactivated, causes the cells to adopt the phenotype of
differentiated podocytes. Using immunocytochemistry,
reverse-transcriptase-polymerase chain reaction, and Western
blotting, direct effects of the glucocorticoid dexamethasone
were studied at concentrations mimicking those achieved in
clinical practice. Dexamethasone was shown to upregulate
expression of nephrin and alpha-tubulin and downregulate
vascular endothelial growth factor (VEGF). The effects on the
podocyte cell cycle were complex with downregulation of p21
(a cell cycle inhibitor) expression and augmentation of podocyte
survival, without any effect on apoptosis [90]. This study
suggests that although the mature podocyte is highly differ-
entiated, it can adapt in response to kidney injury. There may be
an ability for the podocyte to release the ‘molecular brake’ and
perhaps promote proliferation and repair in order to restore
homeostasis. Although no direct connection was established
between abnormal calcium homeostasis and steroids, it is
possible that TRPC6 is involved in the adaptive response of the
podocyte to stress through its interaction with nephrin and other
podocyte proteins [90]. Given previous studies which revealed
that nephrin-deficient mice have TRPC6 mislocalization and
overexpression, it is plausible that blockade may ameliorate the
abnormal slit diaphragm architecture in certain proteinuric renal
diseases [35]. Ideally, blockade of TRPC6 could promote
podocyte proliferation and complex formation.
Evidence also suggests that TRP channels may be involved
in the immunosuppressant action of the calcineurin inhibitor
FK-506, one of the latest therapies for steroid-resistant FSGS
[91]. FK-506 has been determined to affect the interaction of
TRP channels with immunophilins. Immunophilins are pepti-
dyl-prolyl cis/trans isomerases which recognize specific XP
dipeptides in target proteins and are mediators of the immune
system [92]. Goel et al. have shown that TRPL channels interact
with the immunophilin FKBP-59 and that this interaction can be
abrogated by the addition of FK-506 [93]. Furthermore,
TRPC3, TRPC6, and TRPC7 have been shown to co-localize
with the immunophilin FKBP-12, another intracellular target of
FK-506 [94]. Preliminary experiments have shown that the
addition of FK-506 to cells overexpressing TRPC6 caused an
inhibition of channel activity. This work, although in its infancy,suggests a novel mechanism of action for FK-506 and suggests
that impairing TRPC6 activity may also be immunosuppressive.
The effects of FK-506 on steroid-resistant FSGS await a
randomized-controlled trial where if beneficial, future focus on
targeted blocking of the TRPC6 channel should be pursued.
In addition to a possible immunosuppressive effect of
TRPC6 channel blockade, a very recent study of pathologic
cardiac remodeling has further elucidated the intimate connec-
tion between TRPC6 and the calcineurin signaling circuit [95].
In this study, TRPC6 gene expression was shown to be
upregulated in various mouse models of cardiac hypertrophy as
well as human hearts with dilated cardiomyopathies. TRPC6
gene expression was also shown to be regulated by calcineurin
and nuclear factor of activated T cells (NFAT) through a positive
feedback loop. Transgenic mice overexpressing TRPC6 were
shown to develop cardiomegaly, congestive heart failure, and
premature death. Therefore, this study provides further evidence
that TRPC6 overexpression may be pathologic and provides a
strong rationale for therapeutic blockade.
5.3. Blocking TRPC6 channels: Obstacles
The blockade of TRPC6 channels has many challenges.
Firstly, since TRPC6 shares approximately 75% sequence
homology with TRPC3 and TRPC7, creating a construct that is
highly selective will be challenging. Secondly, since TRPC6 is
expressed in a wide variety of human tissues, even if selective
inhibition is achieved, there may be harmful side effects. As
described earlier, the TRPC6 knockout mice produced by
Dietrich et al. were found to be hypertensive [96]. This would
be an extremely untoward side effect of a potential anti-
proteinuric medication. The goal would be to produce a
molecule that is highly specific for TRPC6, a formidable task.
6. Conclusions
Studies of familial nephrotic syndromes have delineated the
importance of the podocyte in normal glomerular function.
Genetic abnormalities in podocyte proteins such as nephrin,
podocin, ACTN4, and CD2AP lead to glomerulosclerosis,
likely due to changes in the slit diaphragm or podocyte
cytoskeleton. One of the latest advances in podocyte biology
has been the unexpected association of familial FSGS with a
mutant variant of TRPC6. The TRPC6 mutation causes an
augmentation of inwardly rectifying calcium currents in the
podocyte cell membrane. The mechanism by which abnormal
calcium homeostasis leads to glomerular injury remains
unknown. In the coming years, research will focus on the
effects of intracellular calcium on the podocyte contractile
apparatus and podocyte life cycle. Perhaps the increase in
intracellular calcium in the podocyte leads to apoptosis,
detachment, or cell cycle arrest during maturation, via either
GPCRs or Ang II. Elucidation of the role of TRPC6 in
glomerular function may also enable clinicians to better treat
idiopathic FSGS, a disease with a generally poor prognosis.
Ang II, a known mediator of kidney injury, has been shown to
augment intracellular calcium currents in mutant TRPC6 mice,
866 N. Mukerji et al. / Biochimica et Biophysica Acta 1772 (2007) 859–868suggesting a therapeutic benefit to blocking TRPC6 channels.
Furthermore, the calcineurin inhibitor FK-506, a potent
immunosuppressive agent, has been shown to impair TRPC6
channel activity in vivo. In addition to therapeutics, the TRPC6
channel may also be useful in the genetic typing of patients.
While far from the mythical “ESRD gene”, polymorphisms of
TRPC6 may act as susceptibility or initiation factors for renal
disease and may help determine which patients would derive
benefit from early, aggressive therapy. Overall, the generous
efforts of multiple families from diverse ethnic backgrounds
have led to significant advances in our understanding of the
podocyte and its effect on glomerular function. Hopefully, the
next few years will see this molecular knowledge translate into
long-lasting clinical benefits.
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